BridgeMD
New treatment option for Trochanteric Syndrome
Official title Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome
ClinicalTrials.gov ID: NCT07396246
What this study is testing
What is Platelet-Rich Plasma Injection?
Platelet-Rich Plasma Injection is an investigational medicine, given as an once-daily injectable medicine, being studied as a potential treatment for trochanteric syndrome.
Also referred to as PRP injection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly affect daily activities and quality of life. Standard treatments include physical therapy, anti-inflammatory medications, and local injections, but many patients continue to experience persistent symptoms.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Diagnosis of GTPS confirmed by clinical and imaging assessments
- Persistent symptoms despite at least 3 months of conservative treatment (e.g., physical therapy, NSAIDs)
- Willingness to participate and provide informed consent
- Availability for follow-up assessments at 1, 3, 6, and 12 months post-treatment
You likely can't join if
- Prior hip surgery or other interventions (e.g., joint replacement, prior PRP injections or embolization)
- Severe osteoarthritis (Tonnis III)
- Active lumbar radiculopathy with pain, numbness, or weakness in a dermatomal distribution
- Contraindications for PRP injections (e.g., active infection, coagulopathy, antiplatelet or anticoagulation therapy,
- Pregnancy or breastfeeding
- Severe comorbidities that would interfere with participation
See the full eligibility criteria
- Diagnosis of GTPS confirmed by clinical and imaging assessments
- Persistent symptoms despite at least 3 months of conservative treatment (e.g., physical therapy, NSAIDs)
- Willingness to participate and provide informed consent
- Availability for follow-up assessments at 1, 3, 6, and 12 months post-treatment
- Prior hip surgery or other interventions (e.g., joint replacement, prior PRP injections or embolization)
- Severe osteoarthritis (Tonnis III)
- Active lumbar radiculopathy with pain, numbness, or weakness in a dermatomal distribution
- Contraindications for PRP injections (e.g., active infection, coagulopathy, antiplatelet or anticoagulation therapy,
- Pregnancy or breastfeeding
- Severe comorbidities that would interfere with participation
- Active cancer or other malignancies
The study team makes the final eligibility decision.
Where it's taking place
- Guimarães, Portugal
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guimarães, Portugal. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.